The effects of Silybum marianum (L.) Gaertn. seed extract on glycemic control in type II diabetic patient's candidate for insulin therapy visiting endocrinology clinic in baqiyatallah hospital in the years of 2006

Journal of Medicinal Plants

Volumn 7, Issue 26, 2008, Pages

  Ramezani, M ^a,d   Azarabadi, M ^b   Fallah Huseini, H ^c   Abdi, H ^a   Baher, G ^b   Huseini, M ^a  

^a BAQIYATALLAH UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b ISLAMIC AZAD UNIVERSITY   (Iran)

^c AVICENNA RESEARCH INSTITUTE   (Iran)

^d Baqiyatallah Medical Sciences University Baqyatallah Hospital   (Iran)

Author keywords

Candidate for insulin therapy; Diabetes mellitus; Silymarin

Indexed keywords

CHOLESTEROL; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; PLACEBO; SILYBUM MARIANUM EXTRACT; SILYMARIN;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALTERNATIVE MEDICINE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CHOLESTEROL BLOOD LEVEL; CHRONIC DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG EFFECT; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HERBAL MEDICINE; HUMAN; HYPERGLYCEMIA; HYPOLIPEMIA; INSULIN RESISTANCE; INSULIN TREATMENT; IRAN; METABOLIC ACIDOSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL; SILYBUM MARIANUM; TRIACYLGLYCEROL BLOOD LEVEL;

SILYBUM; SILYBUM MARIANUM;

EID: 50649124514     PISSN: 2717204X     EISSN: 27172058     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Afkhami M. The prevalence of diabetes mellitus in Yazd province,Iran Fifth international congress of endocrinology. 1999.
2. Larson P, Kronenberg h, melmed Sh, Polonsky K. Williams Textbook of endocrinology, Tenth edition, volume 2, Sunders, 2003, 1427-440.
3. Jafari A. guidance for Diabetes First edd. Ajr publishing Tehran 1380: pp: 120-1.
4. Fallah Huseini H, Fakhrzadeh H, Larijani B, Shikh Samani AH. Review of anti-diabetic medicinal plant used in traditional medicine. J. of Medicinal Plants. 2006; Supplement 2, Diabetes: 1-8.
5. Marles RJ and Farnsworth NR. Antidiabetic plants and their active constituents. Phyomedicine. 1995; 137-16.
6. Huseini HF, Larijani B, Heshmat R, Fakhrzadeh H, Radjabipour B, Toliat T, Raza M. The efficacy of Silybum marianum (L.) Gaertn. (silymarin) in the treatment of type II diabetes: a randomized, double-blind, placebo-controlled, clinical trial. Phytother Res. 2006; 20 (12): 1036-9.
7. Velussi M, Cernigoi AM, De Monte A, Dapas F, Caffau C, Zilli M. Long-term (12 months) treatment with an anti-oxidant drug (silymarin) is effective on hyperinsulinemia, exogenous insulin need and malondialdehyde levels in cirrhotic diabetic patients. J. Hepatol. 1997; 26: 871-9.
8. Bean C. Silybum marianum. Nature conservancy, st. 3 rd California, 785 Market floor. Sanfrancisco. 1985.
9. Vogle G. Studies on pharmacodynamics, site and mechanism of action of silymarin the antihepatotoxic principale from Silybum marianum (L.) Gaert. Arzneim Forsch 1979; 25: 179-85.
10. Sonnenbichler J, Goldberg M, Hane L, Vogl S and Zetl L. Stimulatory effect of silibinin on DNA synthesis in partially hepatectomized rat livers: non-response in hepatoma and other malign cell lines. Biochem. Pharmacol. 1986; 35: 538-41.
11. Velussi M, Cernigoi AM, Viezzoli L, Dapas F, Caffau C, Zilli M. Silymarin reduces hyperinsulinemia, malondialdehyde levels, and daily insulin needs in cirrhotic diabetic patients. Current Therapeutic Research 1993; 53: 533-45.
12. Lirussi F, Beccarello A, Zanette G. Silybin-beta-cyclodextrin in the treatment of patients with diabetes mellitus and alcoholic liver disease. Efficacy study of a new preparation of an antioxidant agent. Diabetes Nutr Metab. 2002; 15 (4): 222-31.
13. Doehmer J, Tewes B, Klein KU, Gritzko K, Muschick H, Mengs U. Assessment of drug-drug interaction for silymarin. Toxicol In Vitro. 2008; 22 (3): 610-7.